Support for regenerative medicines - can the Government and the NHS deliver?

The surprise announcement of a general election on 8th June has generated a flurry of activity from the Commons' and Lords' committees, which have had to wind-up their current inquiries much sooner than expected and release reports on their findings so far. The House of Commons Science and Technology Committee (STC) has had a busy session and their report on regenerative medicine was one of...

ctDNA technology in lung cancer: personalised healthcare in action

Personalisation of cancer care, by prescribing drugs that target specific mutations in patients' tumours, is already a reality. For a subset of patients with non-small cell lung cancer (NSCLC) and whose tumours have a mutation in a gene called EGFR, targeted therapies are available.

Genome editing in medicine - where are we?

As we discussed in a recent blog, the House of Commons Science and Technology Committee's ambitious and wide-reaching inquiry into genomics and genome editing is examining the role that genomic technologies can play in health, agriculture and the environment. The PHG Foundation's written response to the inquiry was one of many sent, and the variety of organisations and individuals responding resul...

Circulating tumour DNA technology: the future of cancer management?

Cancer is an increasing burden on the health system and projected incidence figures – that 1 in 2 of us born after 1960 will be diagnosed with some form of cancer – make for gloomy reading. However, a combination of technological leaps and marginal gains have led to greatly improved survival figures for many cancers; with now 80% of patients surviving more than 10 years post diagnosis for ...

Clinical proteome analysis – the key to personalised medicine?

While the genome contains a list of instructions for the cell written in DNA, the proteome comprises all the proteins within a cell or organism that are coded for by genes within the genome. The proteome is in effect a record of all the proteins that a cell needs to function in a certain state and therefore contains a lot of useful information. By studying and comparing the proteome i...

The ethics of genome editing: where now?

The Nuffield Council on Bioethics published its review on the ethics of genome editing on 30 September, highlighting reproductive editing and editing of livestock as areas of immediate ethical concern; the report also recommended that a range of other issues, including xenotransplantation and cell-based therapies, should be addressed in the near future or kept under review.

AMR tops the international agenda

Antimicrobial resistance (AMR) was high on the political agenda recently, with the  UN high-level meeting on AMR coinciding with the publication of reports on the issue from the UK government and the World Bank. 

Genome editing: promising, but beware the hype

Genome editing - hot or not? View the full infographic here

Liquid biopsy – liquid gold for cancer management?

Liquid biopsy - hot or not? View the full infographic here

The global battle against AMR - can technology lead the way?

The final report of the UK's Review on antimicrobial resistance (AMR) has been published and reinforces the message that the world must act now to tackle an issue that could kill up to 10 million people a year by 2050, up from 700,000 per year today. This comprehensive report covers a broad spectrum of areas for action and it is clear that nothing short of a determined, collaborative worldwide e...

Pathogen surveillance using WGS: forewarned is forearmed

The news late last year that resistance to an antibiotic of last resort, colistin, had been found in China in two species of disease-causing bacteria collected from humans, animals and samples of raw meat naturally caused great alarm. These bacteria, Escherichia coli and Klebsiella pneumoniae, belong to the Enterobacteriaceae, a large group of Gram-negative bacteria that include many species cap...